CN Patent

CN106459111B — 一种抗癌化合物的晶型及其制备方法和用途

Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2019-05-31 · 7y expired

What this patent protects

本发明涉及一种抗癌化合物(R)‑3‑[1‑(2,6‑二氯‑3‑氟苯基)乙氧基]‑5‑[3‑氟苯基‑1‑二甲基膦酰氧‑4‑基]吡啶‑2‑胺的晶型和制备方法，其结构式如式Ⅰ所示。本发明晶型稳定性良好，引湿性低，流动性好，符合医药制剂应用需求。

USPTO Abstract

本发明涉及一种抗癌化合物(R)‑3‑[1‑(2,6‑二氯‑3‑氟苯基)乙氧基]‑5‑[3‑氟苯基‑1‑二甲基膦酰氧‑4‑基]吡啶‑2‑胺的晶型和制备方法，其结构式如式Ⅰ所示。本发明晶型稳定性良好，引湿性低，流动性好，符合医药制剂应用需求。

Drugs covered by this patent

Patent Metadata

Patent number
CN106459111B
Jurisdiction
CN
Classification
—
Expires
2019-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.